PAPSS2

(3'-phosphoadenosine 5'-phosphosulfate synthase 2)

 

  • Alias                                 (According to NCBI)

 
  • ATPSK2 
  • 3'-phosphoadenosine 5'-phosphosulfate synthase 2 
  • 3-prime-phosphoadenosine 5-prime-phosphosulfate synthase 2 
  • Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthethase 2 (PAPS synthethase 2) (PAPSS 2)
    (Sulfurylase kinase 2) (SK2) (SK 2) [Includes: Sulfate adenylyltransferase (EC 2.7.7.4) (Sulfate
    adenylate transferase) (SAT) (ATP-sulfurylase); Adenylyl-sulfate kinase (EC 2.7.1.25)
    (Adenylylsulfate 3'-phosphotransferase) (APS kinase) (Adenosine-5'-phosphosulfate
    3'-phosphotransferase) (3'- phosphoadenosine-5'-phosphosulfate synthetase)].
  • Sulfation is a common modification of endogenous (lipids, proteins, and carbohydrates) and exogenous (xenobiotics and drugs) compounds. In mammals, the sulfate source is 3'-phosphoadenosine 5'-phosphosulfate (PAPS), created from ATP and inorganic sulfate. Two different tissue isoforms encoded by different genes synthesize PAPS. This gene encodes one of the two PAPS synthetases. Defects in this gene cause the Pakistani type of spondyloepimetaphyseal dysplasia. Two alternatively spliced transcript variants that encode different isoforms have been described for this gene
  • Location: 10q23-q24
  • Orientation: plus strand
  • Size: 86546 bp
  • 13 exons
  • DNA sequence (Human): NC_000010.

  • CGH (10q23-24):  Losses (%) - 7.8   Gain (%)  2.2  

  • Mutations and SNPs (According to HGMD and SNP)
  • m-RNA                       (According to NCBI and CGAP)

 

        

  • Pathways and interactions (According to BioCarta, DIP)

  • Protein interactions:
  • Clinical                            (According to OMIM, PubMed)